• On 27 June 2026, QuidelOrtho Corporation (NasdaqGS: QDEL) was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, Russell 2500 Growth, Russell 3000 Growth, and Russell 3000E Growth indices.
• This broad index removal can matter for investors because it often triggers benchmark-tracking funds to adjust their holdings, potentially reshaping trading volumes and the shareholder base.
• We’ll now examine how QuidelOrtho’s removal from multiple Russell growth indices may influence its investment narrative and future investor expectations.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

QuidelOrtho Investment Narrative Recap

To own QuidelOrtho, you need to believe that its core lab and point of care diagnostics can offset shrinking COVID testing and product discontinuations, while integration efforts eventually improve margins. The broad Russell index removals may initially affect trading flows and visibility, but they do not directly change the key near term catalyst of execution on new platforms and cost savings, nor the central risk around ongoing losses and restructuring.

The most relevant recent development is the appointment of a new CFO, Micah Young, effective July 6, 2026. A fresh finance leader arrives just weeks after index removal and follows a year of sizeable net losses and tightened 2026 revenue guidance. For investors focused on whether QuidelOrtho can stabilize its balance sheet and improve earnings quality, this leadership change sits right beside operational progress as a near term catalyst.

Yet alongside the potential upside from new leadership and cost actions, the scale and persistence of recent losses is something investors should be aware of...

QuidelOrtho's narrative projects $3.0 billion revenue and $352.5 million earnings by 2029.

Uncover how QuidelOrtho's forecasts yield a $18.62 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Lowest estimate analysts sounded far more cautious, assuming revenue grows only about 2.9 percent annually with continued losses, and they might now see the Russell removals as reinforcing concerns about high leverage and constrained flexibility.

Explore 2 other fair value estimates on QuidelOrtho - why the stock might be worth just $18.62!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.